27557-86-4

Usage

Uses

Used in Pharmaceutical Research:
2-(naphthalen-1-yl)propan-1-amine is utilized as a key intermediate in the synthesis of various pharmaceutical compounds, contributing to the development of potential new drugs. Its unique structure allows for the creation of molecules with specific therapeutic properties, making it a valuable asset in the search for novel treatments.
Used in Organic Synthesis:
In the field of organic chemistry, 2-(naphthalen-1-yl)propan-1-amine is employed as a versatile building block for the construction of complex organic molecules. Its reactivity and structural characteristics facilitate the synthesis of a wide range of compounds, from simple to highly complex, for use in various applications.
Used in the Development of New Psychoactive Substances:
2-(naphthalen-1-yl)propan-1-amine is also considered for its potential role in the development of new psychoactive substances. Its chemical structure and properties may offer insights into the design of novel compounds with altered or enhanced psychoactive effects, which could be of interest to researchers in the field of psychopharmacology.
Used in Chemical Research:
2-(naphthalen-1-yl)propan-1-amine is a subject of study in chemical research, where its properties and reactivity are explored to gain a deeper understanding of its behavior in various chemical reactions. This knowledge can be applied to improve existing synthetic methods or to develop new ones, ultimately contributing to the advancement of chemical science.

Upstream product

• 24168-42-1 2-(naphthalen-1-yl)propanenitrile 
• 941-98-0 1'-naphthacetophenone 

Downstream Products

• 3900-63-8 (+/-)-3,4,5-Trimethoxy-benzoesaeure-<2-<1>naphthyl-propylamid> 

Relevant academic research and scientific papers

NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME

The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A1 and A2 are each guanidine or a group of the general fomula (ia) ; A3 is a mono- or poly-cyclic heteroaromatic ring contining 1 or 2 heteroatoms ; B1 is a single bond or alkylene group; R1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(=O)-; x is -C(=O)-NH-; n1 is an integer of 1-2; n2 is an integer of 2-3; D is a substituent selected from among various groups.

Synthesis of β-substituted Naphth-1-yl ethylamido derivatives as new melatoninergic agonists

Naphthalene melatoninergic ligands with alkyl groups (Me, Et, Pr, Bz) in the β position of the ethylamido chain were synthesised. The affinity of the compounds for chicken brain melatonin receptors was evaluated using 2-[125I]-iodomelatonin as the radioligand. An increase in the affinity was observed with the β-methyl derivatives and the greatest increase was seen with the (-) enantiomers. The introduction of a 2- or 7-MeO group on the naphthalene ring and the lengthening (Et, Pr) of the alkylamido chain gave potent compounds such as (-)1h (K(i)=24pM). The functional activity of these compounds was evaluated by the aggregation of melanophores in Xenopus laevis tadpoles. The potency to produce lightening of the skin of Xenopus laevis was related to the affinities values of the molecules at melatonin chicken brain receptors. The most potent ligands were found to be full agonists and compound 1h was 25 fold more potent than melatonin in this bioassay. Copyright (C) 1999 Elsevier Science Ltd.